Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination.

[1]  M. Sockrider,et al.  Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. , 2004, The Journal of allergy and clinical immunology.

[2]  K. Papp,et al.  Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants , 2004 .

[3]  A. Elbe-Bürger,et al.  Pimecrolimus does not affect Langerhans cells in murine epidermis , 2003, The British journal of dermatology.

[4]  M. Moser.  Dendritic cells in immunity and tolerance-do they display opposite functions? , 2003, Immunity.

[5]  J. Fay,et al.  Dendritic Cells , 2003, Annals of the New York Academy of Sciences.

[6]  V. Ho,et al.  Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. , 2003, The Journal of pediatrics.

[7]  D. Whalley,et al.  The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. , 2002, Pediatrics.

[8]  J. Ortonne,et al.  Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. , 2002, The Journal of allergy and clinical immunology.

[9]  U. Wahn,et al.  Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. , 2002, Pediatrics.

[10]  K. Kim,et al.  Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. , 2002, Pediatrics.

[11]  N. Davidovitch,et al.  Seasonality trends of Pediculosis capitis and Phthirus pubis in a young adult population: follow‐up of 20 years , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  P. Spuls,et al.  Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel®, SD Z ASM 981) in Patients with Atopic Dermatitis , 2002, Dermatology.

[13]  M. Boguniewicz,et al.  Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. , 2002, Journal of the American Academy of Dermatology.

[14]  A. Stuetz,et al.  Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity. , 2001, Seminars in cutaneous medicine and surgery.

[15]  France,et al.  The seroepidemiology of measles in Western Europe , 2001, Epidemiology and Infection.

[16]  J. Harper,et al.  First experience of topical SDZ ASM 981 in children with atopic dermatitis , 2001, The British journal of dermatology.

[17]  W. Edmunds,et al.  The seroepidemiology of rubella in western Europe , 2000, Epidemiology and Infection.

[18]  E. L. Miller,et al.  The sero-epidemiology of diphtheria in Western Europe , 2000, Epidemiology and Infection.

[19]  A. Winiski,et al.  A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology , 1999, The British journal of dermatology.

[20]  H. Schuurman,et al.  A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology , 1997, The British journal of dermatology.

[21]  B. Hahn,et al.  Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. , 1979, JAMA.

[22]  J. Baxter,et al.  Mechanism of glucocorticoid action: general features, with reference to steroid-mediated immunosuppression. , 1975, Transplantation proceedings.

[23]  W. Butler.  Corticosteroids and immunoglobulin synthesis. , 1975, Transplantation proceedings.

[24]  A. Février,et al.  Immune status of children one to four years of age as determined by history and antibody measurement. , 1973, The New England journal of medicine.

[25]  Strother H. Walker,et al.  Estimation of the probability of an event as a function of several independent variables. , 1967, Biometrika.